Abbott Pays Action $110M for Global Rights to Phase II-Stage Acute Kidney … – Genetic Engineering News
The Deal PipelineAbbott Pays Action $110M for Global Rights to Phase II-Stage Acute Kidney …Genetic Engineering NewsAbbott is paying Denmark's Action Pharma $110 million for global rights to develop and commercialize the latter's AP214, a Pha…